Regulatory T Cells in Endemic Burkitt Lymphoma Patients Are Associated with Poor Outcomes: A Prospective, Longitudinal Study.

Deficiencies in Epstein-Barr virus (EBV)-specific T cell immunosurveillance appear to precede the development of endemic Burkitt lymphoma (eBL), a malaria-associated pediatric cancer common in sub-Saharan Africa. However, T cell contributions to eBL disease progression and survival have not been cha...

Full description

Saved in:
Bibliographic Details
Main Authors: Emily Parsons, Juliana A Otieno, John Michael Ong'echa, Christina E Nixon, John Vulule, Christian Münz, V Ann Stewart, Ann M Moormann
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2016-01-01
Series:PLoS ONE
Online Access:https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0167841&type=printable
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849472602647560192
author Emily Parsons
Juliana A Otieno
John Michael Ong'echa
Christina E Nixon
John Vulule
Christian Münz
V Ann Stewart
Ann M Moormann
author_facet Emily Parsons
Juliana A Otieno
John Michael Ong'echa
Christina E Nixon
John Vulule
Christian Münz
V Ann Stewart
Ann M Moormann
author_sort Emily Parsons
collection DOAJ
description Deficiencies in Epstein-Barr virus (EBV)-specific T cell immunosurveillance appear to precede the development of endemic Burkitt lymphoma (eBL), a malaria-associated pediatric cancer common in sub-Saharan Africa. However, T cell contributions to eBL disease progression and survival have not been characterized. Our objective was to investigate regulatory and inflammatory T cell responses in eBL patients associated with clinical outcomes. By multi-parameter flow cytometry, we examined peripheral blood mononuclear cells from 38 eBL patients enrolled in a prospective cohort study in Kisumu, Kenya from 2008-2010, and 14 healthy age-matched Kenyan controls. Children diagnosed with eBL were prospectively followed and outcomes categorized as 2-year event-free survivors, cases of relapses, or those who died. At the time of diagnosis, eBL children with higher CD25+Foxp3+ regulatory T (Treg) cell frequencies were less likely to survive than patients with lower Treg frequencies (p = 0·0194). Non-survivors also had higher absolute counts of CD45RA+Foxp3lo naïve and CD45RA-Foxp3hi effector Treg subsets compared to survivors and healthy controls. Once patients went into clinical remission, Treg frequencies remained low in event-free survivors. Patients who relapsed, however, showed elevated Treg frequencies months prior to their adverse event. Neither concurrent peripheral blood EBV load nor malaria infection could explain higher Treg cell frequencies. CD8+ T cell PD-1 expression was elevated in all eBL patients at time of diagnosis, but relapse patients tended to have persistently high PD-1 expression compared to long-term survivors. Non-survivors produced more CD4+ T-cell IL-10 in response to both Epstein-Barr Nuclear Antigen-1 (EBNA-1) (p = 0·026) and the malaria antigen Plasmodium falciparum Schizont Egress Antigen-1 (p = 0·0158) compared to survivors, and were concurrently deficient in (EBNA-1)-specific CD8+ T-cell derived IFN-γ production (p = 0·002). In addition, we identified the presence of Foxp3-IL10+ regulatory Type 1 cells responding to EBNA-1 in contrast to the malaria antigen tested. These novel findings suggest that poor outcomes in eBL patients are associated with a predominantly immuno-regulatory environment. Therefore, Treg frequencies could be a predictive biomarker of disease progression and manipulation of Treg activity has potential as a therapeutic target to improve eBL survival.
format Article
id doaj-art-c8471c3a08db499b8d98b5a142abbcbb
institution Kabale University
issn 1932-6203
language English
publishDate 2016-01-01
publisher Public Library of Science (PLoS)
record_format Article
series PLoS ONE
spelling doaj-art-c8471c3a08db499b8d98b5a142abbcbb2025-08-20T03:24:29ZengPublic Library of Science (PLoS)PLoS ONE1932-62032016-01-011112e016784110.1371/journal.pone.0167841Regulatory T Cells in Endemic Burkitt Lymphoma Patients Are Associated with Poor Outcomes: A Prospective, Longitudinal Study.Emily ParsonsJuliana A OtienoJohn Michael Ong'echaChristina E NixonJohn VululeChristian MünzV Ann StewartAnn M MoormannDeficiencies in Epstein-Barr virus (EBV)-specific T cell immunosurveillance appear to precede the development of endemic Burkitt lymphoma (eBL), a malaria-associated pediatric cancer common in sub-Saharan Africa. However, T cell contributions to eBL disease progression and survival have not been characterized. Our objective was to investigate regulatory and inflammatory T cell responses in eBL patients associated with clinical outcomes. By multi-parameter flow cytometry, we examined peripheral blood mononuclear cells from 38 eBL patients enrolled in a prospective cohort study in Kisumu, Kenya from 2008-2010, and 14 healthy age-matched Kenyan controls. Children diagnosed with eBL were prospectively followed and outcomes categorized as 2-year event-free survivors, cases of relapses, or those who died. At the time of diagnosis, eBL children with higher CD25+Foxp3+ regulatory T (Treg) cell frequencies were less likely to survive than patients with lower Treg frequencies (p = 0·0194). Non-survivors also had higher absolute counts of CD45RA+Foxp3lo naïve and CD45RA-Foxp3hi effector Treg subsets compared to survivors and healthy controls. Once patients went into clinical remission, Treg frequencies remained low in event-free survivors. Patients who relapsed, however, showed elevated Treg frequencies months prior to their adverse event. Neither concurrent peripheral blood EBV load nor malaria infection could explain higher Treg cell frequencies. CD8+ T cell PD-1 expression was elevated in all eBL patients at time of diagnosis, but relapse patients tended to have persistently high PD-1 expression compared to long-term survivors. Non-survivors produced more CD4+ T-cell IL-10 in response to both Epstein-Barr Nuclear Antigen-1 (EBNA-1) (p = 0·026) and the malaria antigen Plasmodium falciparum Schizont Egress Antigen-1 (p = 0·0158) compared to survivors, and were concurrently deficient in (EBNA-1)-specific CD8+ T-cell derived IFN-γ production (p = 0·002). In addition, we identified the presence of Foxp3-IL10+ regulatory Type 1 cells responding to EBNA-1 in contrast to the malaria antigen tested. These novel findings suggest that poor outcomes in eBL patients are associated with a predominantly immuno-regulatory environment. Therefore, Treg frequencies could be a predictive biomarker of disease progression and manipulation of Treg activity has potential as a therapeutic target to improve eBL survival.https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0167841&type=printable
spellingShingle Emily Parsons
Juliana A Otieno
John Michael Ong'echa
Christina E Nixon
John Vulule
Christian Münz
V Ann Stewart
Ann M Moormann
Regulatory T Cells in Endemic Burkitt Lymphoma Patients Are Associated with Poor Outcomes: A Prospective, Longitudinal Study.
PLoS ONE
title Regulatory T Cells in Endemic Burkitt Lymphoma Patients Are Associated with Poor Outcomes: A Prospective, Longitudinal Study.
title_full Regulatory T Cells in Endemic Burkitt Lymphoma Patients Are Associated with Poor Outcomes: A Prospective, Longitudinal Study.
title_fullStr Regulatory T Cells in Endemic Burkitt Lymphoma Patients Are Associated with Poor Outcomes: A Prospective, Longitudinal Study.
title_full_unstemmed Regulatory T Cells in Endemic Burkitt Lymphoma Patients Are Associated with Poor Outcomes: A Prospective, Longitudinal Study.
title_short Regulatory T Cells in Endemic Burkitt Lymphoma Patients Are Associated with Poor Outcomes: A Prospective, Longitudinal Study.
title_sort regulatory t cells in endemic burkitt lymphoma patients are associated with poor outcomes a prospective longitudinal study
url https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0167841&type=printable
work_keys_str_mv AT emilyparsons regulatorytcellsinendemicburkittlymphomapatientsareassociatedwithpooroutcomesaprospectivelongitudinalstudy
AT julianaaotieno regulatorytcellsinendemicburkittlymphomapatientsareassociatedwithpooroutcomesaprospectivelongitudinalstudy
AT johnmichaelongecha regulatorytcellsinendemicburkittlymphomapatientsareassociatedwithpooroutcomesaprospectivelongitudinalstudy
AT christinaenixon regulatorytcellsinendemicburkittlymphomapatientsareassociatedwithpooroutcomesaprospectivelongitudinalstudy
AT johnvulule regulatorytcellsinendemicburkittlymphomapatientsareassociatedwithpooroutcomesaprospectivelongitudinalstudy
AT christianmunz regulatorytcellsinendemicburkittlymphomapatientsareassociatedwithpooroutcomesaprospectivelongitudinalstudy
AT vannstewart regulatorytcellsinendemicburkittlymphomapatientsareassociatedwithpooroutcomesaprospectivelongitudinalstudy
AT annmmoormann regulatorytcellsinendemicburkittlymphomapatientsareassociatedwithpooroutcomesaprospectivelongitudinalstudy